Titre : Benzocycloheptènes

Benzocycloheptènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Alendronate
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzocycloheptènes : Questions médicales les plus fréquentes", "headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-11", "dateModified": "2025-03-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzocycloheptènes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hydrocarbures aromatiques polycycliques", "url": "https://questionsmedicales.fr/mesh/D011084", "about": { "@type": "MedicalCondition", "name": "Hydrocarbures aromatiques polycycliques", "code": { "@type": "MedicalCode", "code": "D011084", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dibenzocycloheptènes", "alternateName": "Dibenzocycloheptenes", "url": "https://questionsmedicales.fr/mesh/D003986", "about": { "@type": "MedicalCondition", "name": "Dibenzocycloheptènes", "code": { "@type": "MedicalCode", "code": "D003986", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Amitriptyline", "alternateName": "Amitriptyline", "url": "https://questionsmedicales.fr/mesh/D000639", "about": { "@type": "MedicalCondition", "name": "Amitriptyline", "code": { "@type": "MedicalCode", "code": "D000639", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.100" } } }, { "@type": "MedicalWebPage", "name": "Butaclamol", "alternateName": "Butaclamol", "url": "https://questionsmedicales.fr/mesh/D002069", "about": { "@type": "MedicalCondition", "name": "Butaclamol", "code": { "@type": "MedicalCode", "code": "D002069", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.230" } } }, { "@type": "MedicalWebPage", "name": "Cyproheptadine", "alternateName": "Cyproheptadine", "url": "https://questionsmedicales.fr/mesh/D003533", "about": { "@type": "MedicalCondition", "name": "Cyproheptadine", "code": { "@type": "MedicalCode", "code": "D003533", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Loratadine", "alternateName": "Loratadine", "url": "https://questionsmedicales.fr/mesh/D017336", "about": { "@type": "MedicalCondition", "name": "Loratadine", "code": { "@type": "MedicalCode", "code": "D017336", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Loratadine", "alternateName": "Loratadine", "url": "https://questionsmedicales.fr/mesh/D017336", "about": { "@type": "MedicalCondition", "name": "Loratadine", "code": { "@type": "MedicalCode", "code": "D017336", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340.500" } } }, { "@type": "MedicalWebPage", "name": "Maléate de dizocilpine", "alternateName": "Dizocilpine Maleate", "url": "https://questionsmedicales.fr/mesh/D016291", "about": { "@type": "MedicalCondition", "name": "Maléate de dizocilpine", "code": { "@type": "MedicalCode", "code": "D016291", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.380" } } }, { "@type": "MedicalWebPage", "name": "Nortriptyline", "alternateName": "Nortriptyline", "url": "https://questionsmedicales.fr/mesh/D009661", "about": { "@type": "MedicalCondition", "name": "Nortriptyline", "code": { "@type": "MedicalCode", "code": "D009661", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.535" } } }, { "@type": "MedicalWebPage", "name": "Protriptyline", "alternateName": "Protriptyline", "url": "https://questionsmedicales.fr/mesh/D011530", "about": { "@type": "MedicalCondition", "name": "Protriptyline", "code": { "@type": "MedicalCode", "code": "D011530", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.650" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Benzocycloheptènes", "alternateName": "Benzocycloheptenes", "code": { "@type": "MedicalCode", "code": "D001567", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jiatian Li", "url": "https://questionsmedicales.fr/author/Jiatian%20Li", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Xiangwen Tan", "url": "https://questionsmedicales.fr/author/Xiangwen%20Tan", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Huanfeng Jiang", "url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Wanqing Wu", "url": "https://questionsmedicales.fr/author/Wanqing%20Wu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells.", "datePublished": "2023-09-27", "url": "https://questionsmedicales.fr/article/37758809", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-43377-3" } }, { "@type": "ScholarlyArticle", "name": "Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36239756", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00198-022-06570-0" } }, { "@type": "ScholarlyArticle", "name": "Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.", "datePublished": "2023-04-22", "url": "https://questionsmedicales.fr/article/37086385", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40273-023-01270-x" } }, { "@type": "ScholarlyArticle", "name": "Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36119926", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/1213278" } }, { "@type": "ScholarlyArticle", "name": "Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study.", "datePublished": "2023-02-19", "url": "https://questionsmedicales.fr/article/36833451", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes14020524" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés polycycliques", "item": "https://questionsmedicales.fr/mesh/D011083" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures aromatiques polycycliques", "item": "https://questionsmedicales.fr/mesh/D011084" }, { "@type": "ListItem", "position": 4, "name": "Benzocycloheptènes", "item": "https://questionsmedicales.fr/mesh/D001567" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzocycloheptènes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzocycloheptènes", "description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzocycloheptènes", "description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzocycloheptènes", "description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzocycloheptènes", "description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzocycloheptènes", "description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzocycloheptènes", "description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les benzocycloheptènes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des techniques de spectroscopie et de chromatographie." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les benzocycloheptènes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire." } }, { "@type": "Question", "name": "Les benzocycloheptènes sont-ils détectables dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour ces composés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des benzocycloheptènes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques." } }, { "@type": "Question", "name": "Les benzocycloheptènes causent-ils des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique." } }, { "@type": "Question", "name": "Les benzocycloheptènes affectent-ils le système respiratoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition excessive peut entraîner des irritations respiratoires." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux benzocycloheptènes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire." } }, { "@type": "Question", "name": "Y a-t-il des formations pour manipuler ces composés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs." } }, { "@type": "Question", "name": "Quels sont les risques en milieu industriel ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate." } }, { "@type": "Question", "name": "Des réglementations existent-elles pour leur usage ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie." } }, { "@type": "Question", "name": "Comment évaluer les risques d'exposition ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail." } }, { "@type": "Question", "name": "Comment traiter une intoxication aux benzocycloheptènes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques." } }, { "@type": "Question", "name": "Y a-t-il des antidotes pour ces composés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider en cas d'allergie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques." } }, { "@type": "Question", "name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation peut être nécessaire en cas de symptômes graves." } }, { "@type": "Question", "name": "Comment gérer les effets à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces composés ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée." } }, { "@type": "Question", "name": "Les benzocycloheptènes peuvent-ils causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires." } }, { "@type": "Question", "name": "Y a-t-il des effets sur la reproduction ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales." } }, { "@type": "Question", "name": "Peut-on développer des allergies à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée." } }, { "@type": "Question", "name": "Les benzocycloheptènes affectent-ils le système immunitaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections." } }, { "@type": "Question", "name": "Qui est le plus à risque d'exposition ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque." } }, { "@type": "Question", "name": "L'environnement de travail influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition." } } ] } ] }

Sources (159 au total)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.

In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower in... To determine whether the anti-fracture efficacy of sequential therapy with teriparatide, followed by alendronate is superior to that of monotherapy with alendronate, a prospective, randomized, open-la... Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture. Patients were randomly assigned (1:1) to receive the sequ... Between October 2014 and June 2020, 505 patients in the sequential therapy group and 506 in the monotherapy group were enrolled. Of these, 489 and 496, respectively, were included in the main analysis... Once-weekly injection of teriparatide, followed by alendronate resulted in a significantly lower incidence of morphometric vertebral fracture than alendronate monotherapy in women with osteoporosis wh...

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.

Abaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported in postmenopausal women with osteoporosis. The cost effectiveness of sequential t... A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gain... Over the full age range, sequential ABL/ALN led to more QALYs for lower costs than sequential unbranded TPTD/ALN, while no treatment was dominated (more QALYs, lower costs) by ALN monotherapy. The cos... Sequential therapy using ABL/ALN may be cost effective compared with generic ALN monotherapy in US men aged ≥ 50 years at high fracture risk, especially in those aged ≥ 60 years. Unbranded TPTD/ALN an...

Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures.

This research aims to investigate and analyze the impact of alendronate sodium (ALN) plus elcatonin (EC) in treating postoperative bone pain (BP) in patients with osteoporotic fractures (OPFs).... One hundred and thirty-eight cases of OPFs admitted between July 2018 and July 2021 were selected, of which 68 cases receiving ALN were set as the control group and 70 cases receiving ALN plus EC were... Better postoperative BP relief, higher overall response rate, and lower complication rate were identified in the research group versus the control group. On the other hand, the research group presente... For OPF patients, ALN plus EC contributes to significantly reduced postoperative BP, improved clinical efficacy, higher treatment safety, and better bone metabolism, which has high clinical applicatio...

Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study.

Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is u... The aim of this work was to investigate the influence of combinations of potential risk alleles (genetic profiles) associated with response to anti-osteoporotic treatment in postmenopausal women with ... A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed. The bone mineral density (BMD; g/cm... A total of 56 subjects were responders to alendronate and 26 subjects were non-responders. Carriers of the G-C-G-C profile (constructed from rs700518, rs1800795, rs2073618 and rs3102735) were predispo... Our findings highlight the importance of the identified profiles for the pharmacogenetics of alendronate therapy in osteoporosis....

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.

A retrospective study of 121 patients who stopped denosumab (Dmab) then received no treatment (NT), risedronate (RIS), alendronate (ALN), or zoledronic acid (ZOL). Bone density (spine and hip) during ... Denosumab (Dmab) discontinuation is associated with bone loss and multiple vertebral fractures. The purpose was to compare bone mineral density (BMD) change in patients following Dmab discontinuation ... In a review of 121 patients aged 71.2 ± 8.1 years, discontinuing Dmab (mean 5.4 doses), 33 received NT and 88 received BP (22 RIS; 34 ALN; 32 ZOL). BMD change after 1 year was compared between groups ... Following Dmab discontinuation, LS mean change (g/cm... Subsequent treatment with ALN or ZOL but not NT and RIS mitigates BMD loss after Dmab discontinuation....